Alnylam Pharmaceuticals
ALNY
423 hedge funds and large institutions have $16.6B invested in Alnylam Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 131 increasing their positions, 161 reducing their positions, and 68 closing their positions.
42% more call options, than puts
Call options by funds: $486M | Put options by funds: $343M
0.85% less ownership
Funds ownership: 94.83% → 93.98% (-0.85%)
5% less funds holding
Funds holding: 444 → 423 (-21)
11% less capital invested
Capital invested by funds: $18.6B → $16.6B (-$2.07B)
18% less first-time investments, than exits
New positions opened: 56 | Existing positions closed: 68
19% less repeat investments, than reductions
Existing positions increased: 131 | Existing positions reduced: 161
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$609M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$232M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$87.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$47.3M |
| 5 |
Morgan Stanley
New York
|
+$39.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$244M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$173M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$113M |
| 4 |
Holocene Advisors
New York
|
-$113M |
| 5 |
JP Morgan Chase
New York
|
-$90.1M |
ALNY Hedge Fund Activity: Q2 2022 in Review
423 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2022, worth a combined $16.6B — down 11% from $18.6B a quarter earlier.
Sellers outnumbered buyers: 68 funds closed out of ALNY and 56 opened new positions — a net loss of 12 holders — while 161 trimmed existing stakes and 131 added.
The largest buyer was Capital World Investors, adding an estimated $609M. The largest seller was Fidelity Investments, cutting an estimated $244M.
- 423 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2022, down from 444 in Q1 2022.
- Funds reported $16.6B of Alnylam Pharmaceuticals stock for Q2 2022, down 11% quarter-over-quarter.
- 56 funds opened new Alnylam Pharmaceuticals positions in Q2 2022 and 68 closed out, a net change of -12 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2022 was Capital World Investors, an estimated $609M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2022 was Fidelity Investments, an estimated $244M sold.
Based on aggregated 13F filings for Q2 2022.